Arrowhead Pharmaceuticals
ARWR
41.37
-2.28
-5.22%
Arrowhead Pharmaceuticals
US · ARWR
#1569 by market cap
Listed 1970
41.37
-2.28
-5.22%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
C-
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Hold to Buy on 2026-04-21.
Analyst consensus 11 analysts
Buy
Avg price target 106.63 +157.7%
Price target rangecurrent 41.37
Low74.00
Avg106.63
High126.00
Buy 91%
Hold 9%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Piper Sandler | -- | Buy | 126.00 |
| 2026-11-13 | BofA Securities | -- | Buy | -- |
| 2026-11-13 | Morgan Stanley | -- | Buy | 106.00 |
| 2026-11-13 | Stifel | -- | Buy | 96.00 |
| 2026-11-13 | RBC Capital | -- | Buy | 100.00 |
| 2026-11-11 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-11-10 | Piper Sandler | -- | Buy | 126.00 |
| 2026-11-10 | B. Riley Securities | -- | Buy | 123.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-10-15 | Piper Sandler | -- | Buy | 126.00 |
| 2026-10-15 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-10-15 | J.P. Morgan | -- | Buy | -- |
| 2026-10-14 | Citi | -- | Buy | 108.00 |
| 2026-10-14 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-10-12 | BofA Securities | -- | Buy | 100.00 |
| 2026-09-24 | Goldman Sachs | -- | Hold | 74.00 |
| 2026-09-21 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-09-16 | Citi | -- | Buy | -- |
| 2026-09-15 | J.P. Morgan | -- | Buy | -- |
| 2026-09-09 | Citi | -- | Buy | 108.00 |
| 2026-09-08 | Citi | -- | Buy | 108.00 |
| 2026-09-01 | H.C. Wainwright | -- | Buy | 120.00 |
| 2026-08-31 | Morgan Stanley | -- | Buy | 120.00 |
| 2026-08-31 | Stifel | -- | Buy | 104.00 |
| 2026-08-31 | J.P. Morgan | -- | Buy | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-21 | Morgan Stanley | Hold → Buy | 100.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q4 | 2026-11-12 | After close | ±8.47% | +1.34% (in line) |
| 2026/Q3 | 2026-08-04 | After close | ±8.92% | -2.99% (in line) |
| 2026/Q2 | 2026-05-07 | After close | ±7.25% | -6.75% (in line) |
| 2026/Q1 | 2026-02-05 | After close | ±11.93% | -0.19% (in line) |
| 2025/Q4 | 2025-11-25 | After close | ±13.52% | +23.34% (beat) |
| 2025/Q3 | 2025-08-07 | After close | ±13.30% | +2.24% (in line) |
| 2025/Q2 | 2025-05-12 | After close | ±11.99% | +9.38% (in line) |
| 2025/Q1 | 2025-02-10 | After close | ±10.83% | -5.17% (in line) |
| 2024/Q4 | 2024-11-26 | After close | ±15.02% | +24.23% (beat) |
| 2024/Q3 | 2024-08-08 | After close | ±12.75% | -9.44% (in line) |
| 2024/Q2 | 2024-05-09 | After close | ±10.35% | -10.68% (beat) |
| 2023/Q4 | 2023-11-29 | After close | ±12.00% | -26.85% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Arrowhead Pharmaceuticals discussion 0 comments